Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Apple, Inc. (AAPL) Tops Q3 EPS by 5c, Sales Light
- After-Hours Stock Movers 7/22: (PBYI) (TLM) (ISRG) Higher; (XOOM) (XLNX) (AAPL) Lower (more...)
- Market Wrap: CPI Gains 0.3% in June; Another Ack-Attack on Herbalife; Apple Bruised on Q2 Phone Sales
- Microsoft Corp. (MSFT) Posts Q4 EPS of 55c; Revs Top Expectations
- Juniper Networks, Inc. (JNPR) Tops Q2 EPS by 2c, Issues Light Q3 Outlook
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
You May Also Be Interested In
- UPDATE: Deutsche Bank's (DB) U.S. Ops Suffer from Various Reporting Issues - WSJ
- Halozyme Therapeutics (HALO) Continues Enrollment in PEGPH20 Phase 2
- Galena Biopharma (GALE) Enters Licensing Agreement for Zuplenz Oral Soluable Film
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!